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Abstract 
Objective 
We sought to characterise C9orf72 expansions in relation to genetic ancestry and 
age at onset (AAO), and to use these parameters to discriminate the behavioural 
from the language variant syndrome, in a large pan-European cohort of 
frontotemporal lobar degeneration (FTLD) cases. 
Methods 
We evaluated expansions frequency in the entire cohort (n=1396; bvFTD [n=800], 
PPA [n=495] and FTLD-MND [n=101]). We then focused on the bvFTD and PPA 
cases and tested for association between expansion status, syndromes, genetic 
ancestry, and AAO applying statistical tests comprising Fisher’s Exact, ANOVA with 
Tukey post-hoc tests, and logistic and non-linear mixed-effects model regressions. 
Results 
We found C9orf72 pathogenic expansions in 4% of all cases (56/1396). Expansion 
carriers differently distributed across syndromes: 12/101 FTLD-MNDs (11.9%), 
40/800 bvFTDs (5%) and 4/495 of PPAs (0.8%). While addressing population-
substructure through principal component analysis (PCA), we defined 2 patients 
groups with Central/Northern (n=873) and Southern European (n=523) ancestry.  
The proportion of expansion carriers was significantly higher in bvFTDs compared to 
PPAs (5% vs. 0.8% [p=2.17x10-5; OR=6.4; CI:2.31-24.99]), as well as in individuals 
with Central/Northern European compared to Southern European ancestry (4.4% vs. 
1.8% [p=1.1x10-2; OR=2.5; CI:1.17-5.99]). Pathogenic expansions and 
Central/Northern European ancestry independently and inversely correlated with 
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 AAO. Our prediction model (based on expansions status, genetic ancestry and AAO) 
predicted a diagnosis of bvFTD with 64% accuracy. 
Conclusions Our results indicate correlation between pathogenic C9orf72 
expansions, AAO, PCA-based Central/Northern European ancestry and a diagnosis 
of bvFTD, implying to complex genetic risk-architectures differently underpinning the 
behavioural and language variant syndromes.
AC
CE
PT
ED
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
 Introduction 
Frontotemporal lobar degeneration (FTLD) refers to the second most common form 
of young-onset dementia after Alzheimer’s Disease (AD) 1. The major clinical 
syndromes are behavioural variant (bvFTD) 2 and/or language dysfunctions, broadly 
called primary progressive aphasia (PPA); the latter is subdivided in semantic 
dementia (SD) (or semantic variant PPA) and progressive non-fluent aphasia 
(PNFA) (or nonfluent/agrammatic variant PPA) 2, 3. FTLD can also occur together 
with motor neuron disease (FTLD-MND, or amyotrophic lateral sclerosis [FTLD-
ALS]) in a continuous spectrum of phenotypes 4.  
In FTLD, repeat expansions in C9orf72 5 have been previously reported to occur in 
~25% 6-10 of familial and ~6% 11 of sporadic cases (i.e. individuals with no clear 
familial history and/or genetic aetiology 12). Several studies had shown high 
frequencies of pathogenic C9orf72 expansions in Northern vs. Southern European 
patients (North-South axis), especially in historically isolated populations (such as 
the Finnish 13, 14), leading to the hypothesis that a Scandinavian founder might be at 
the basis of the spread of the C9orf72 expansion 15. Other studies (based on the 
geographical location of the recruiting sites) challenged the North-South axis concept 
either reporting a high frequency (~25%) of pathogenic expansions in the Spanish 
population 10, or implying to the existence of more than one risk-haplotype 16-19. 
FTLD patients with abnormal C9orf72 repeat expansions exhibit marked 
phenotypical and pathological heterogeneity, thus suggesting presence of additional 
(genetic and environmental) modifiers 20. Despite conflicting studies reporting either 
direct or inverse correlation between repeat length and age at onset (AAO), C9orf72 
expansions have been suggested to act as a genetic modifier of AAO 16, 21-24. 
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 We here analysed 1396 FTLD cases gathered through the IFGC (International FTD-
Genetics Consortium; https://ifgcsite.wordpress.com/) phase-III initiative, aiming at (i) 
characterising C9orf72 expansions in relation to genetic ancestry and AAO, and (ii) 
assessing the usefulness of these parameters in discriminating the behavioural from 
the language variant syndrome.  
 
Methods 
Cohort, clinical phenotyping 
FTLD cases were collected between 2016 and 2018 (within the IFGC phase-III 
project [https://ifgcsite.wordpress.com/ongoing-projects/]). The samples were 
recruited by clinicians and research groups who are part of the IFGC network and 
based in Italy, Spain, Germany, the Netherlands, Belgium, UK, Sweden, Norway, 
Slovenia, and USA (Supplementary Table 1: https://doi.org/10.5522/04/12418157). 
Patients were diagnosed at each contributing site (Supplementary Table 2: 
https://doi.org/10.5522/04/12418157) in a harmonised fashion according to international 
consensus criteria such as the Neary et al (for FTLD), Rascovsky et al (for bvFTD), 
Gorno-Tempini et al (for PPA [SD or PNFA]) and Strong et al (for FTLD-MND) 
criteria 2-4, 25.  
Genotyping, C9orf72 repeat expansions and analysis cohorts 
Thousand four-hundred and fifty-four (1454) cases were successfully genotyped by 
means of the NeuroArray 26 on the Illumina Infinium platform. Genotypes were used 
to inform on population substructure via standard principal component analysis 
(PCA) (Supplementary Figure 1: https://doi.org/10.5522/04/12418157), which led to 
the exclusion of 44 population outliers, and allowed to address population-
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 substructure within the cohort (we identified 2 distinct [‘Nordic’ and ‘Mediterranean’] 
clusters; Supplementary Figure 2: https://doi.org/10.5522/04/12418157). We also 
assessed cryptic relatedness and excluded 14 first or second degree related 
individuals, leaving a cohort of 1396 cases (group 0) – for which C9orf72 expansion 
status (i.e. presence/absence of pathogenic expansions) was known – for analyses. 
Frequencies of pathogenic expansions were assessed in group 0 and further 
analyses were performed in: i) 1295 cases (group 1: n = 800 bvFTDs and n = 495 
PPAs) with known C9orf72 expansion status; ii) 1179 cases (group 2; n = 756 
bvFTDs and n = 423 PPAs) with known C9orf72 expansion status and age at onset 
(AAO) data available, and; iii) 734 cases (group 3; n = 462 bvFTDs and n = 272 
PPAs) with AAO and repeat counts (rc; screened via repeat-primed PCR [RP-PCR] 
[c.f. 27, 28], see Supplementary Materials and Methods and Supplementary Figure 
3: https://doi.org/10.5522/04/12418157) data available (Figure 1A).   
Statistical analyses 
We first assessed the frequency of pathogenic expansions in the entire cohort (group 
0). The information on presence/absence of expansions was used as a binary 
variable (0 = absence of expansion; 1 = presence of expansion). We then 
investigated differences in the frequencies of pathogenic expansions across bvFTDs 
and PPAs, and the ‘Nordic’ and ‘Mediterranean’ clusters in group 1 (Fisher’s Exact 
test) and in group 3 (logistic regression); in the latter, we used repeat counts (rc) as 
a categorical variable (using ‘no’, ‘short’, ‘intermediate’ and ‘long’ as factor levels) 
considering the following 4 categories: ‘no’ expansions (rc = 2/3), ‘short’ expansions 
(4 ≤ rc ≤ 8), ‘intermediate’ expansions (9 ≤ rc ≤ 24) and ‘long’ expansions (rc ≥ 25), 
the latter representing expansions in the pathogenic range (c.f. 10, 22; see also 
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 Supplementary Materials and Methods and Supplementary Figure 3: 
https://doi.org/10.5522/04/12418157).  
We then evaluated association between AAO and syndrome, genetic ancestry and 
expansions (i.e. presence/absence used as a binary variable, see above) alone and 
with genetic ancestry as a covariate in group 2 (t-test and logistic regression) and in 
group 3 (t-test, ANOVA with Tukey post-hoc test, and logistic and linear mixed-
effects model). In the latter case, we used rc as a categorical variable (see above). 
Finally, we sought to build a model to predict syndrome (bvFTD vs. PPA) using (i) 
presence/absence of pathogenic expansions (as binary variable [see above] for 
group 2) or (ii) rc (as categorical variable [see above] for group 3), ancestry as binary 
variable and AAO as continuous variable using logistic regression models (i.e. the 
leave-one-out cross validation [LOOCV] and the K-fold models). A summary of the 
analyses workflow can be found in Figure 1B. 
All analyses were performed using R studio (version 3.6.0, studio version 1.2.1335).  
C9orf72 locus risk-haplotype  
Twenty (rs1110264, rs1110155, rs2150336, rs1161680, rs2589054, rs1822723, 
rs4879515, rs895023, rs868856, rs1977661, rs903603, rs12349820, rs10122902, 
rs2282241, rs1948522, rs1982915, rs2453556, rs702231, rs696826 and rs247751) 
of the original 42 SNPs constituting the (Finnish) risk-haplotype 29 were available on 
the NeuroArray 26. We filtered out 7 markers in order to keep 13 informative SNPs 
(rs1822723, rs4879515, rs868856, rs1977661, rs903603, rs10122902, rs2282241, 
rs1948522, rs1982915, rs2453556, rs702231, rs696826, rs2477518) matching 13 of 
the 20 used in Mok et al 15. We evaluated the proportion of cases carrying at least 
one risk-allele (as in Mok et al 15) for each marker assessing expansion vs. non-
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 expansion carriers (with/without ancestry stratification).  
Standard Protocol Approvals, Registrations and Patient Consents 
Each contributing site obtained written informed consent from all patients to be part 
of extended genetic studies; the current study is approved under Institutional Review 
Board (IRB),approval #9811/001. 
Data availability 
All data generated or analysed during this study are included in this published article (and 
Supplementary files 1 and 2 at: https://doi.org/10.5522/04/12418157. 
 
Results 
C9orf72 expansions frequency and syndromes 
We assessed the frequency of pathogenic expansions in the entire cohort and 
across the different syndromes in the group 0 cases (Figure 1). Four percent of all 
cases (56/1396 [4%]) carried pathogenic expansions. These were most frequent in 
FTLD-MNDs (12/101 [11.9%]) followed by bvFTDs (40/800 [5%]) and PPAs (4/495 
[0.8%]). The higher prevalence of pathogenic expansions in bvFTDs vs. PPAs was 
statistically significant (Fisher’s Exact test: p = 2.17x10-5; OR = 6.4; 95% CI: 2.31 – 
24.99 Table 1). We further explored this finding in the group 3 cases using logistic 
regression to assess association between expansion length (represented by 4 repeat 
counts [rc] factor levels – ‘short’, ‘intermediate’ and ‘long’ expansions, tested against 
‘no’ expansions) and syndromes (bvFTD vs. PPA). Expansion length discriminated 
bvFTD from PPA with a trend that was significant in the ‘intermediate’ (p = 4.7x10-2; 
OR = 1.6; CI: 0.0061 [2.5%] – 0.94 [97.5%]) and ‘long’ (p = 1.9x10-3; OR = 7.2; CI: 
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 0.86 [2.5%] – 3.45 [97.5%]) rc ranges (with a ~90% probability of a bvFTD diagnosis 
supported by the latter; Supplementary Table 3 
https://doi.org/10.5522/04/12418157). 
C9orf72 expansions (and repeat counts [rc]) and genetic ancestry  
We performed PCA (PC1 vs. PC2, Supplementary Figure 2A; PC1 vs. PC3, 
Supplementary Figures 2B: https://doi.org/10.5522/04/12418157) to cluster the 
group 1 cases based on their genetic make-up. There were 2 major clusters: cluster-
1 (‘Mediterranean’) included most of the cases (439/500 [87.8%]) recruited from 
Southern European sites (Italy and Spain); cluster-2 (‘Nordic’) included most of the 
cases (627/795 [78.8%]) recruited from Central and Northern European sites 
(Belgium, The Netherlands, Germany, UK, Norway and Sweden). Samples recruited 
from Eastern European (Slovenia) and North American sites distributed across both 
clusters – although with a higher prevalence within cluster-2 (167/795 [21%]) vs. 
cluster-1 (42/500 [8.4%]). 
We observed a significantly higher prevalence of pathogenic expansions in the 
‘Nordic’ (35/795 [4.4%]) vs. the ‘Mediterranean’ (9/500 [1.8%]) cluster (Fisher’s Exact 
test: p = 1.1x10-2; OR = 2.5; CI: 1.17 – 5.99 Table 2). We further evaluated this 
finding in the group 3 cases using logistic regression to assess association between 
expansion length (see above) and genetic ancestry. Expansion length discriminated 
the ‘Nordic’ from ‘Mediterranean’ cluster with a trend that was significant in the 
‘intermediate’ (p = 9.7x10-4, OR = 2.2; CI: 0.32 [2.5%] – 1.25 [97.5%]) and ‘long’ (p = 
4.7x10-4, OR = 9.3; CI: 1.12 [2.5%] – 3.7 [97.5%]) rc ranges (with a ~90% probability 
of ‘Nordic’ ancestry supported by the latter; Supplementary Table 4: 
https://doi.org/10.5522/04/12418157). 
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 Provided differences in syndromes prevalence and distribution across the ‘Nordic’ 
and ‘Mediterranean’ clusters – bvFTD (469/795 [59%] vs. 331/500 [66.2%]) and PPA 
(326/795 [41%] vs. 169/500 [33.8%]), respectively (Supplementary Table 5: 
https://doi.org/10.5522/04/12418157) – we analysed the distribution of pathogenic 
expansions across syndromes and clusters. Stratified Fisher’s Exact test showed 
significant differences in the distribution of the pathogenic expansions between 
bvFTD and PPA in the’ Nordic’ (but not the ‘Mediterranean’) cluster (p = 1x10-4; OR = 
7.87; 95% CI: 2.43 – 40.52), and between the ‘Nordic’ and the ‘Mediterranean’ clusters 
for the bvFTD (but not PPA) syndrome (p = 1.9x10-2; OR = 2.95; 95% CI: 1.31 – 7.52), 
suggesting that ancestry (‘Nordic’) and syndrome (bvFTD) are independently 
associated with pathogenic expansions (Table 3). 
C9orf72 repeat expansions (and counts [rc]) and age at onset (AAO) 
We assessed AAO in the group 2 cases (Figure 1). Mean AAO was significantly 
different between the bvFTD (61.7) and PPA (64) syndromes (t-test: p = 1.86x10-5; 
CI: -3.34 – -1.25), and the ‘Nordic’ (61.3) and ‘Mediterranean’ (64.3) clusters (t-test: 
p = 1.16x10-7; CI: 1.86 – 4.03) (Supplementary Table 6A and B; Figure 2A: 
https://doi.org/10.5522/04/12418157). We then assessed the relationship between 
pathogenic expansions and AAO via logistic regression. First, we identified a 
significant correlation between a decrease in AAO and presence of pathogenic 
expansions (p = 7.7x10-4; R2 = 0.008; CI: -8.05 [2.5%] – -2.13 [97.5%]). When we 
included genetic ancestry in the model we observed a significant correlation with a 
decrease in AAO, no difference in using either cluster (p = 2.3x10-3; CI: -7.5 [2.5%] – 
-1.63 [97.5%] for pathogenic expansions; p = 2.3x10-7 ; CI: -3.9 [2.5%] – -1.77 
[97.5%] for cluster; R2=0.03) or PC1 (p = 2.1x10-3; CI: -7.5 [2.5%] – -1.66 [97.5%] for 
pathogenic expansions; p = 6.4x10-7; CI: 30.1 [2.5%] – 68.9 [97.5%] for PC1; 
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 R2=0.028) as covariate and an almost 4-fold goodness of fit increase 
(Supplementary Table 7A, B and C: https://doi.org/10.5522/04/12418157). Of note, 
when comparing the two regression models (with/without genetic ancestry as 
covariate) through the log-likelihood R2 ratio test, the difference (between the 2 
models) appeared not to be not due to chance (p < 10-12) (Supplementary Table 7B 
and C: https://doi.org/10.5522/04/12418157). 
We further evaluated the relationship between expansion length (represented by 4 
repeat counts [rc] factor levels – ‘short’, ‘intermediate’ and ‘long’ expansions, tested 
against ‘no’ expansions) and AAO in the group 3 cases (Figure 1). First, we 
independently analysed association between AAO and: i) genetic ancestry – mean 
AAO 60.9 and 64.6 in the ‘Nordic’ and ‘Mediterranean’ cluster, respectively (t-test: p 
= 2.1x10-7; CI: 2.32 – 5.09; Supplementary Table 8A: 
https://doi.org/10.5522/04/12418157); ii) syndrome – mean AAO 61.7 and 63.5 in the 
bvFTD and PPA syndromes, respectively (t-test: p = 9.1x10-3; CI: -3.11 – -0.44; 
Supplementary Table 8B: https://doi.org/10.5522/04/12418157), and; iii) expansion 
length – mean AAO 63.2 for both ‘no’ and ‘short’ expansions, 61 for ‘intermediate’ 
expansions and 58 for ‘long’ expansions (ANOVA: p = 3.6x10-2; CI: -10.2 – -0.23 for 
‘long’ vs. ‘no’ expansions) (Supplementary Table 8D; Figure 2B and C: 
https://doi.org/10.5522/04/12418157). We then assessed the relationship between 
expansion length (see above) and AAO via logistic regression. First, we identified a 
significant correlation between a decrease in AAO and both ‘intermediate’ and ‘long’ 
expansions (p = 4x10-2; CI: -4.36 [2.5%] – -0.96 [97.5%] for ‘intermediate’ and p = 
7x10-3; CI: -9.05 [2.5%] – -1.43 [97.5%] for ‘long’ expansions; R2 = 0.017) 
(Supplementary Table 9A: https://doi.org/10.5522/04/12418157). When we 
included genetic ancestry in the model we observed a significant correlation with a 
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 decrease in AAO, no difference in using either cluster (p = 4.7x10-2; CI: -7.65 [2.5%] 
– -0.05 [97.5%] for ‘long’ vs. ‘no’ expansion; p = 2.38x10-6; CI: -4.73 [2.5%] – -1.97 
[97.5%] for cluster; R2 = 0.045) or PC1 (p = 5.98x10-2; CI: -7.5 [2.5%] – 0.14 [97.5%] 
for ‘long’ vs. ‘no’ expansion; p = 1.2x10-6; CI: 39.8 [2.5%] – 92.9 [97.5%] for PC1; 
R2=0.047) as covariate and an almost 3-fold goodness of fit increase 
(Supplementary Table 9A, B and C: https://doi.org/10.5522/04/12418157). Of note, 
when comparing the two regression models (with/without genetic ancestry as 
covariate) through the log-likelihood R2 ratio test, the difference (between the 2 
models) appeared not to be due to chance (p < 10-12) (Supplementary Table 9B 
and C: https://doi.org/10.5522/04/12418157). These findings were further supported 
by non-linear mixed-effects model regression using genetic ancestry as random 
effect covariate (for ‘long’ vs. ‘no’ expansion; see Supplementary Table 10: 
https://doi.org/10.5522/04/12418157). 
C9orf72 locus risk-haplotype 
All of the risk alleles for the 13 markers – shortest informative stretch of the original 
risk-haplotype 15, 29 available to us – were seen in: i) 40/56 (71.4%) expansion 
carriers vs. 380/1340 (28.4%) non-expansion carriers in the entire cohort; ii) 33/47 
(70.2%) expansion carriers vs. 228/826 (27.6%) non-expansion carriers in the 
‘Nordic’ cluster, and; iii) 7/9 (77.8%) expansion carriers vs. 152/514 (29.6%) non-
expansion carriers in the ‘Mediterranean’ cluster. Comparing the proportion of risk-
allele carriers (expansion vs. non-expansion carriers) for each single marker, 5/13 
markers (rs4879515, rs868856, rs903603, rs2282241, rs2453556) were significant in 
the ‘Nordic’ cluster, none in the ‘Mediterranean’ cluster (Supplementary Figure 4: 
https://doi.org/10.5522/04/12418157). Rs2477518 showed variable frequencies for 
the risk-allele (T) across expansion vs. non-expansion carriers (and the 2 clusters), 
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 thus making this most probably a negligible marker within this stretch, as hinted 
previously 15, 17. Rs3849942, previously suggested as surrogate marker for the risk 
haplotype 15, was not among the SNPs available to us. We used rs868856, 
displaying strongest LD with rs3849942 (D’=0.96; R2=0.7; https://ldlink.nci.nih.gov/), 
as informative proxy: the risk-allele segregated differently across expansion vs. non-
expansion carriers in the ‘Nordic’ and ‘Mediterranean’ cluster (as  for rs2453556) 
possibly suggesting these 2 as the most conserved markers of the original risk-
haplotype across populations in expansion carriers (highlighted in blue in 
Supplementary Figure 4: https://doi.org/10.5522/04/12418157). 
Syndrome prediction 
We then sought to build a model to predict syndrome (bvFTD vs. PPA) and assess 
its accuracy. We analysed both groups 2 and 3 cases using expansion status 
(presence/absence of expansion for group 2, and the 4 rc factor levels for group 3 
[see materials and methods]), genetic ancestry (using either ‘cluster’ or ‘PC1’) as 
binary variables, and AAO as a continuous variable in logistic regression models. We 
observed an accuracy of ~0.64 (group 2; Supplementary Table 11: 
https://doi.org/10.5522/04/12418157) and ~0.62 (group 3; Supplementary Table 12: 
https://doi.org/10.5522/04/12418157) in predicting bvFTD, whilst there were no 
differences in the outcome when using either ‘cluster’ or ‘PC1’ as covariates in both 
(LOOCV and K-fold) models.AC
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Discussion 
This study aimed to characterise C9orf72 expansions in relation to genetic ancestry 
and age at onset (AAO), and to assess the usefulness of these parameters in 
discriminating the behavioural from the language variant syndrome, in a large pan-
European cohort of 1396 FTLD cases. 
To the best of our knowledge, the current work is unique in that, prior characterising 
the expansions, we excluded population-substructure bias using genome-wide 
genotyping data to cluster the cases on the basis of their genetic make-up. After 
principal component analysis (PCA) we identified two distinct clusters including 
samples with geographical ancestry corresponding to Southern Europe 
(‘Mediterranean’ cluster) and Central/Northern Europe (‘Nordic’ cluster). Our 
analyses not only showed that patients from the ‘Nordic’ cluster presented 
significantly higher frequency of pathogenic C9orf72 expansions compared to the 
‘Mediterranean’ cluster, but also that a core stretch of markers (n = 8) of the Finnish 
risk haplotype 29 appeared to be conserved across the ‘Nordic’ expansion carriers, 
whereas there was a similar tendency for (just) 2 of such markers in the 
‘Mediterranean’ expansion carriers. Several studies had shown high frequencies of 
long C9orf72 expansions in Northern vs. Southern European patients (North-South 
axis)13-15. Other studies (based on the geographical location of the recruiting sites) 
challenged the North-South axis concept 10, or the founder effect implying to the 
existence of more than one risk-haplotype 16-19. All this taken together, our current 
data appear to support the North-South axis hypothesis and suggest that 
rearrangements (and instability) 16, 19 at the C9orf72 locus might have occurred 
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 reducing the level of conservation of the original risk haplotype across the European 
population. 
We found pathogenic expansions in ~4% of all cases and that the proportion of 
expansion carriers was significantly higher in bvFTDs compared to PPAs. The fact 
that we overall identified significant association between pathogenic expansions and 
a diagnosis of bvFTD, and Central/Northern European ancestry – findings for the 
most in line with previous reports 8, 10, 13, 20, 30-34 – suggests that C9orf72 expansions 
might serve as useful genetic fingerprint to define subpopulations of FTLD patients 
(Figure 3). Of note, we observed a trend of association with syndrome (bvFTD) and 
genetic ancestry (Central/Northern European) already supported by the 
‘intermediate’ repeat counts (9 ≤ rc ≤ 24) category. This appears in line with previous 
reports suggesting that individuals with 7 to 24 alleles might have an increased risk 
to convert to carriers of pathological repeat expansions10, 22 and may, altogether, be 
useful information in the context of diagnostics. 
Despite some previous conflicting reports of direct (or inverse) correlation between 
C9orf72 expansions and AAO 16, 21, 23, we (as others 22, 24) found a significant inverse 
correlation between C9orf72 expansion length and AAO. Additionally, and 
interestingly, our data also indicates that Central/Northern European genetic 
ancestry contributes to a decreased AAO (independently from the expansions) 
possibly implying to a more complex genetic signature (or architecture), and 
subsequently molecular mechanisms, underpinning this very feature. Clearly, 
disease mechanisms that involve C9orf72 expansion length and AAO are complex, 
thus it is likely that additional factors might further modulate their relationship and 
effect on the phenotype (see also Babić Leko et al 5). 
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 While using expansion length, genetic ancestry and AAO in a regression model to 
discriminate behavioural from language variant subtypes, we found that such 
parameters did support a prediction of bvFTD with 64% accuracy. 
Our results have a number of implications. First, provided that significant variation 
exists in the genetic architecture of the Caucasian population 35, genetic variability 
characterising and differentiating ‘Nordic’ vs. ‘Mediterranean’ subjects (such as in the 
case of our cohort) might influence predisposition to harbouring longer repeat 
expansions. In other repeat expansion diseases – e.g. Huntington’s disease (HD) or 
other microsatellite diseases, including myotonic dystrophy and spinocerebellar  
ataxias 35 – the presence of specific haplogroups in Western European populations 
occurs with a manifold increase in prevalence of repeats compared to other ethnic 
groups and populations 36. Second, different genetic risk-architectures underpinning 
different (and possibly genetically more homogeneous) subpopulations of patients 
may exist within the FTLD population. 
In a nutshell, our results imply that a significantly higher proportion of FTLD cases, 
with ‘Nordic’ rather than ‘Mediterranean’ genetic ancestry, is likely to develop bvFTD 
in presence of  ‘intermediate’ and ‘long’ (pathogenic) expansions, whilst ‘long’ 
(pathogenic) expansions are (almost) negligible in PPAs, regardless of ancestry. 
Clearly, multiple factors including genetic heterogeneity, epigenetic changes, 
ethnicity, as well as environmental factors and habits that may subsist within and 
across multicultural cohorts, all together, contribute to disease predisposition, onset 
and progression 22, 37, 38. These concepts, reinforced by our study, warrant further 
characterisation of genetic, environmental, and additional clinical measures to fine-
tune models able to predict disease outcome to complement diagnostic criteria, and 
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 possibly assist, in the near future, in the identification of informative cohorts for 
tailored clinical trials and the development of effective personalised therapies.  
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 Figures legends 
Figure 1. Cohorts (A) and analysis workflow (B). 
AAO = age at onset; logistic/cluster = logistic regression using cluster as covariate; 
logistic/PC1 = logistic regression using PC1 as covariate; Loocv = leave one out 
cross validation regression model; k-fold regression model. 
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Figure 2. Association between AAO and: ancestry; syndrome; expansion length. 
(A): AAO in the group 2 cases. Mean AAO bvFTD (61.7) and PPA (64) (t-test: p = 
1.86x10-5; CI: -3.34--1.25); mean AAO ‘Nordic’ (61.3) and ‘Mediterranean’ (64.3) 
clusters (t-test: p = 1.16x10-7; CI: 1.86-4.03). (B): AAO in the group 3 cases. Mean 
AAO bvFTD (61.7) and PPA (63.5) (t-test: p = 9.1x10-3; CI: -3.11--0.44), mean AAO 
‘Nordic’ (60.9) and ‘Mediterranean’ (64.6) (t-test: p = 2.1x10-7; CI: 2.32-5.09). (C): 
AAO in the group 3 cases. Mean AAO for both ‘no’ and ‘short’ expansions (63.2), for 
‘intermediate’ expansions (61) and for ‘long’ expansions (58) evaluated via ANOVA 
test. 
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Figure 3. Patients subpopulations (bvFTD and PPA syndromes) based on C9orf72 
expansions genetic signatures and ancestry. 
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 Tables 
Table 1. Frequency of expansion carriers in the entire cohort and by syndrome. 
Summary of expansions carriers frequency in the entire cohort (n = 1396) and across 
syndromes. The higher prevalence of expansion carriers in bvFTD vs. the PPA is statistically 
significant: *Fisher’s exact test performed to statistically evaluate the difference between the 
occurrence of pathogenic expansions in the bvFTD vs. the PPA syndromes: p = 2.17x10-5; 
odds ratio (OR) = 6.4; 95% confidence interval (CI): 2.31-24.99. 
 
Cohort n of cases Expansion 
carriers Frequency 
bvFTD 800 40 5%* 
PPA 495 4 0.8%* 
FTLD-MND 101 12 11.9% 
Total 1396 56 4% 
 
 
 
 
Table 2. Frequency of expansion carriers in the ‘Nordic’ and ‘Mediterranean’ clusters. 
The higher prevalence of expansion carriers in the ‘Nordic’ vs. the ‘Mediterranean’ cluster is 
statistically significant: *Fisher’s exact test: p = 1.1x10-2; OR = 2.5; 95% CI: 1.17-5.99. 
 
 
Genetic 
ancestry n of cases 
Expansion 
carriers Frequency 
Nordic 795 35 4.4%* 
Mediterranean 500 9 1.8%* 
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 Table 3. Stratified Fisher’s exact tests comparing prevalence of pathogenic 
expansions across bvFTD and PPA and the ‘Nordic’ and ‘Mediterranean’ clusters. 
P-values presented in the table are corrected for multiple testing statistics. Prior correction p-
values were as follows: * (uncorrected) Fisher’s exact test: p = 4.7x10-3; OR = 2.95; 95% CI: 
1.31-7.52 → significant difference in the prevalence of bvFTD expansion carriers in the 
‘Nordic’ vs. the ‘Mediterranean’ cluster; # (uncorrected) Fisher’s exact test p = 2.7x10-5; OR = 
7.87; 95% CI: 2.43-40.52 → significant difference in the prevalence of expansion carriers in 
bvFTDs vs. PPAs within the Nordic cluster. 
 
 
Subtype/Ancestry Expansion range  
bvFTD pathogenic non-pathogenic Fisher's Exact Test 
Mediterranean 8 323 
Nordic 32 437 p = 1.9x10
-2
* 
        
Ancestry/Subtype Expansion range  
Mediterranean pathogenic non-pathogenic Fisher's Exact Test 
bvFTD 8 323 
PPA 1 168 p = 1 
Nordic       
bvFTD 32 437 
PPA 3 323 p = 1x10
-4#
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